Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 8debebf6-af94-4ba7-8d67-c801f4ea27eb

Avastin

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-01-06
Captured
2026-09-09T23:37:54.830918+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 ) 1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC). Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ]. 1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC). 1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults. 1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). 1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. 1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 1.7 Hepatocellular Carcinoma Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Full extracted label fields
application numbers
  1. BLA125085
boxed warning exact
    brand names
    1. Avastin
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e
    generic names
    1. BEVACIZUMAB
    id
    8debebf6-af94-4ba7-8d67-c801f4ea27eb
    indications and usage exact
    1. 1 INDICATIONS AND USAGE Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 ) 1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC). Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ]. 1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC). 1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults. 1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). 1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. 1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 1.7 Hepatocellular Carcinoma Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
    indications and usage tables exact
      is original packager
      1. true
      manufacturer names
      1. Genentech, Inc.
      matched search terms
      1. cancer
      2. carcinoma
      3. glioblastoma
      package ndcs
      1. 50242-060-01
      2. 50242-060-10
      3. 50242-061-01
      4. 50242-061-10
      product ndcs
      1. 50242-060
      2. 50242-061
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
      1. Indications and Usage ( 1.1 ) 9/2022 Dosage and Administration ( 2.2 ) 9/2022 Warnings and Precautions, Infusion-Related Reactions ( 5.9 ) 9/2022
      record type
      complete_spl_indications_section_candidate
      routes
      1. INTRAVENOUS
      rxcuis
      1. 1657066
      2. 1657068
      3. 1657073
      4. 1657074
      source batch
      file
      /private/tmp/cancer-full-research/indications/raw/labels-00500.json
      meta
      disclaimer
      Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
      last updated
      2026-09-09
      results
      limit
      100
      skip
      500
      total
      830
      sha256
      424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
      url
      https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=500&sort=id%3Aasc
      source url
      https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
      spl effective date
      2025-01-06
      spl effective time
      20250106
      spl set id
      939b5d1f-9fb2-4499-80ef-0607aa6b114e
      spl version
      39
      substance names
      1. BEVACIZUMAB
      uniis
      1. 2S9ZZM9Q9V
      verification flags
      1. oncology_keyword_candidate_not_clinically_classified
      2. spl_text_not_verified_identical_to_latest_approved_label
      3. individual_indications_not_split_or_reconciled
      Drugs@FDA application source records
      1. application number
        BLA125085
        payload
        all indexed label documents
        1. Appl No
          125085
          Application Docs Date
          2004-02-27 00:00:00
          Application Docs ID
          18771
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          1
          Submission Type
          ORIG
        2. Appl No
          125085
          Application Docs Date
          2006-04-21 00:00:00
          Application Docs ID
          18772
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          67
          Submission Type
          SUPPL
        3. Appl No
          125085
          Application Docs Date
          2006-06-21 00:00:00
          Application Docs ID
          18773
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          74
          Submission Type
          SUPPL
        4. Appl No
          125085
          Application Docs Date
          2009-05-05 00:00:00
          Application Docs ID
          18774
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          169
          Submission Type
          SUPPL
        5. Appl No
          125085
          Application Docs Date
          2011-09-30 00:00:00
          Application Docs ID
          18775
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          225
          Submission Type
          SUPPL
        6. Appl No
          125085
          Application Docs Date
          2012-05-07 00:00:00
          Application Docs ID
          18776
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          238
          Submission Type
          SUPPL
        7. Appl No
          125085
          Application Docs Date
          2012-11-28 00:00:00
          Application Docs ID
          18777
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          265
          Submission Type
          SUPPL
        8. Appl No
          125085
          Application Docs Date
          2013-04-01 00:00:00
          Application Docs ID
          18778
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          267
          Submission Type
          SUPPL
        9. Appl No
          125085
          Application Docs Date
          2013-12-17 00:00:00
          Application Docs ID
          18779
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          285
          Submission Type
          SUPPL
        10. Appl No
          125085
          Application Docs Date
          2014-08-14 00:00:00
          Application Docs ID
          18780
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          301
          Submission Type
          SUPPL
        11. Appl No
          125085
          Application Docs Date
          2014-11-14 00:00:00
          Application Docs ID
          18781
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          305
          Submission Type
          SUPPL
        12. Appl No
          125085
          Application Docs Date
          2015-12-02 00:00:00
          Application Docs ID
          18782
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          312
          Submission Type
          SUPPL
        all submission records
        1. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          340
          Submission Status
          AP
          Submission Status Date
          2022-09-18 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        2. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          337
          Submission Status
          AP
          Submission Status Date
          2020-12-09 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        3. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          336
          Submission Status
          AP
          Submission Status Date
          2020-10-09 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        4. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          334
          Submission Status
          AP
          Submission Status Date
          2020-09-30 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        5. Appl No
          125085
          Review Priority
          PRIORITY
          Submission Class Code ID
          2
          Submission No
          332
          Submission Status
          AP
          Submission Status Date
          2020-05-29 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        6. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          331
          Submission Status
          AP
          Submission Status Date
          2019-06-20 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        7. Appl No
          125085
          Review Priority
          N/A
          Submission Class Code ID
          4
          Submission No
          329
          Submission Status
          AP
          Submission Status Date
          2019-04-03 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        8. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          324
          Submission Status
          AP
          Submission Status Date
          2018-04-30 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        9. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          323
          Submission Status
          AP
          Submission Status Date
          2018-06-13 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        10. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          319
          Submission Status
          AP
          Submission Status Date
          2017-12-05 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        11. Appl No
          125085
          Review Priority
          PRIORITY
          Submission Class Code ID
          2
          Submission No
          317
          Submission Status
          AP
          Submission Status Date
          2016-12-06 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        12. Appl No
          125085
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          312
          Submission Status
          AP
          Submission Status Date
          2015-12-01 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        application number
        BLA125085
        approval interpretation
        Application linkage and approved submission are not indication-level current approval verification
        current indication status
        not_reconciled
        has approved submission record
        true
        latest approved submission date
        2022-09-18
        latest label selection rule
        max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
        latest posted label documents
        1. Appl No
          125085
          Application Docs Date
          2022-09-20 00:00:00
          Application Docs ID
          72113
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          340
          Submission Type
          SUPPL
        official application record
        Appl No
        125085
        Appl Public Notes
        Appl Type
        BLA
        Sponsor Name
        GENENTECH
        openfda application present
        true
        products
        1. Active Ingredient
          BEVACIZUMAB
          Appl No
          125085
          Drug Name
          AVASTIN
          Form
          VIAL; INTRAVENOUS
          Product No
          001
          Reference Drug
          0
          Reference Standard
          Strength
          100MG
          marketing status
          1. Prescription
        2. Active Ingredient
          BEVACIZUMAB
          Appl No
          125085
          Drug Name
          AVASTIN
          Form
          VIAL; INTRAVENOUS
          Product No
          002
          Reference Drug
          0
          Reference Standard
          Strength
          400MG
          marketing status
          1. Prescription

      Source passages and status connections

      Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

      Passage 1 · positive indication candidate
      application numbers
      1. BLA125085
      brand names
      1. Avastin
      classification reasons
      1. explicit_positive_indication_predicate
      2. tumor_or_malignant_hematology_words_in_positive_statement
      clinical review status
      pending
      content role
      positive_indication_candidate
      context span
      end
      444
      end exclusive
      true
      exact text
      1 INDICATIONS AND USAGE Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on
      label id
      8debebf6-af94-4ba7-8d67-c801f4ea27eb
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
      start
      0
      current approval status
      not_reconciled
      duplicate text group
      dup-9caa46f1cd3d46d4e209
      extraction review status
      automated_candidate_pending_source_review
      generic names
      1. BEVACIZUMAB
      id
      ind-span-e7b242f99e9267ecf731
      label id
      8debebf6-af94-4ba7-8d67-c801f4ea27eb
      positive predicate support span
      end
      91
      end exclusive
      true
      exact text
      is a vascular endothelial growth factor inhibitor indicated
      label id
      8debebf6-af94-4ba7-8d67-c801f4ea27eb
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
      start
      32
      qualifier mentions
      1. context exact
        ial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemoth
        kind
        biomarker
        polarity
        not_inferred
        span
        end
        142
        end exclusive
        true
        exact text
        Metastatic colorectal cancer
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        114
      2. context exact
        ial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemoth
        kind
        stage_or_setting
        polarity
        not_inferred
        span
        end
        142
        end exclusive
        true
        exact text
        Metastatic colorectal cancer
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        114
      3. context exact
        h intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
        kind
        prior_therapy_or_line
        polarity
        not_inferred
        span
        end
        243
        end exclusive
        true
        exact text
        second-line treatment
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        222
      4. context exact
        dicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
        kind
        regimen
        polarity
        not_inferred
        span
        end
        243
        end exclusive
        true
        exact text
        in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        144
      regulatory links
        schema version
        0.1.0
        source batch sha256
        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
        source defined aliases
        1. abbreviation
          NSCLC
          definition exact
          non–small cell lung cancer
          definition span
          end
          2647
          end exclusive
          true
          exact text
          non–small cell lung cancer (NSCLC)
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          2613
        source span
        end
        244
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        0
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
        spl effective date
        2025-01-06
        spl set id
        939b5d1f-9fb2-4499-80ef-0607aa6b114e
        spl version
        39
        structured fields status
        not_extracted_no_values_inferred_from_mentions
        structured indication
        age
        Source null
        approval pathway
        Source null
        biomarker and test
        Source null
        disease stage
        Source null
        limitations
        Source null
        line
        Source null
        prior therapy
        Source null
        regimen
        Source null
        tumor histology
        Source null
        use intent
        tumor_directed_candidate
        Passage 2 · positive indication candidate
        application numbers
        1. BLA125085
        brand names
        1. Avastin
        classification reasons
        1. inherited_predicate_from_same_label_section_requires_review
        2. tumor_or_malignant_hematology_words_in_positive_statement
        clinical review status
        pending
        content role
        positive_indication_candidate
        context span
        end
        696
        end exclusive
        true
        exact text
        endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer,
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        45
        current approval status
        not_reconciled
        duplicate text group
        dup-817684f69459ae6a877f
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. BEVACIZUMAB
        id
        ind-span-0a13aaaf1e0161e0a285
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        positive predicate support span
        end
        91
        end exclusive
        true
        exact text
        is a vascular endothelial growth factor inhibitor indicated
        label id
        8debebf6-af94-4ba7-8d67-c801f4ea27eb
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
        start
        32
        qualifier mentions
        1. context exact
          ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoro
          kind
          biomarker
          polarity
          not_inferred
          span
          end
          281
          end exclusive
          true
          exact text
          Metastatic colorectal cancer
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          253
        2. context exact
          ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoro
          kind
          stage_or_setting
          polarity
          not_inferred
          span
          end
          281
          end exclusive
          true
          exact text
          Metastatic colorectal cancer
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          253
        3. context exact
          can- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
          kind
          prior_therapy_or_line
          polarity
          not_inferred
          span
          end
          495
          end exclusive
          true
          exact text
          second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          387
        4. context exact
          ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
          kind
          regimen
          polarity
          not_inferred
          span
          end
          462
          end exclusive
          true
          exact text
          in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevac
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          283
        regulatory links
          schema version
          0.1.0
          source batch sha256
          424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
          source defined aliases
          1. abbreviation
            NSCLC
            definition exact
            non–small cell lung cancer
            definition span
            end
            2647
            end exclusive
            true
            exact text
            non–small cell lung cancer (NSCLC)
            label id
            8debebf6-af94-4ba7-8d67-c801f4ea27eb
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
            start
            2613
          source span
          end
          496
          end exclusive
          true
          exact text
          ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          245
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
          spl effective date
          2025-01-06
          spl set id
          939b5d1f-9fb2-4499-80ef-0607aa6b114e
          spl version
          39
          structured fields status
          not_extracted_no_values_inferred_from_mentions
          structured indication
          age
          Source null
          approval pathway
          Source null
          biomarker and test
          Source null
          disease stage
          Source null
          limitations
          Source null
          line
          Source null
          prior therapy
          Source null
          regimen
          Source null
          tumor histology
          Source null
          use intent
          tumor_directed_candidate
          Passage 3 · limitation of use
          application numbers
          1. BLA125085
          brand names
          1. Avastin
          classification reasons
          1. negative_or_not_established_clause
          clinical review status
          pending
          content role
          limitation_of_use
          context span
          end
          790
          end exclusive
          true
          exact text
          with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent gli
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
          start
          297
          current approval status
          not_reconciled
          duplicate text group
          dup-1cc39b5e060460821b87
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. BEVACIZUMAB
          id
          ind-span-0b6abc3fd0d11c6fe859
          label id
          8debebf6-af94-4ba7-8d67-c801f4ea27eb
          positive predicate support span
          Source null
          qualifier mentions
          1. context exact
            ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer.
            kind
            stage_or_setting
            polarity
            not_inferred
            span
            end
            589
            end exclusive
            true
            exact text
            adjuvant treatment of colon cancer
            label id
            8debebf6-af94-4ba7-8d67-c801f4ea27eb
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
            start
            555
          regulatory links
            schema version
            0.1.0
            source batch sha256
            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
            source defined aliases
            1. abbreviation
              NSCLC
              definition exact
              non–small cell lung cancer
              definition span
              end
              2647
              end exclusive
              true
              exact text
              non–small cell lung cancer (NSCLC)
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              2613
            source span
            end
            590
            end exclusive
            true
            exact text
            ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer.
            label id
            8debebf6-af94-4ba7-8d67-c801f4ea27eb
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
            start
            497
            source url
            https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
            spl effective date
            2025-01-06
            spl set id
            939b5d1f-9fb2-4499-80ef-0607aa6b114e
            spl version
            39
            structured fields status
            not_extracted_no_values_inferred_from_mentions
            structured indication
            age
            Source null
            approval pathway
            Source null
            biomarker and test
            Source null
            disease stage
            Source null
            limitations
            Source null
            line
            Source null
            prior therapy
            Source null
            regimen
            Source null
            tumor histology
            Source null
            use intent
            not_applicable
            Passage 4 · unclassified context
            application numbers
            1. BLA125085
            brand names
            1. Avastin
            classification reasons
            1. no_unambiguous_positive_indication_predicate
            clinical review status
            pending
            content role
            unclassified_context
            context span
            end
            968
            end exclusive
            true
            exact text
            nd-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination wit
            label id
            8debebf6-af94-4ba7-8d67-c801f4ea27eb
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
            start
            391
            current approval status
            not_reconciled
            duplicate text group
            dup-7692d73137b9418f71dd
            extraction review status
            automated_candidate_pending_source_review
            generic names
            1. BEVACIZUMAB
            id
            ind-span-8cf4039f36c95aa4818f
            label id
            8debebf6-af94-4ba7-8d67-c801f4ea27eb
            positive predicate support span
            Source null
            qualifier mentions
            1. context exact
              ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for
              kind
              biomarker
              polarity
              not_inferred
              span
              end
              687
              end exclusive
              true
              exact text
              metastatic non-squamous non-small cell lung
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              644
            2. context exact
              ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non
              kind
              stage_or_setting
              polarity
              not_inferred
              span
              end
              611
              end exclusive
              true
              exact text
              Unresectable
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              599
            3. context exact
              ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung c
              kind
              stage_or_setting
              polarity
              not_inferred
              span
              end
              629
              end exclusive
              true
              exact text
              locally advanced
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              613
            4. context exact
              ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and pac
              kind
              stage_or_setting
              polarity
              not_inferred
              span
              end
              675
              end exclusive
              true
              exact text
              recurrent or metastatic non-squamous non-sma
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              631
            5. context exact
              cancer, in combination with carboplatin and paclitaxel for first-line treatment.
              kind
              prior_therapy_or_line
              polarity
              not_inferred
              span
              end
              767
              end exclusive
              true
              exact text
              first-line treatment
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              747
            6. context exact
              rent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
              kind
              regimen
              polarity
              not_inferred
              span
              end
              767
              end exclusive
              true
              exact text
              in combination with carboplatin and paclitaxel for first-line treatment
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              696
            regulatory links
              schema version
              0.1.0
              source batch sha256
              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
              source defined aliases
              1. abbreviation
                NSCLC
                definition exact
                non–small cell lung cancer
                definition span
                end
                2647
                end exclusive
                true
                exact text
                non–small cell lung cancer (NSCLC)
                label id
                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                start
                2613
              source span
              end
              768
              end exclusive
              true
              exact text
              ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              591
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
              spl effective date
              2025-01-06
              spl set id
              939b5d1f-9fb2-4499-80ef-0607aa6b114e
              spl version
              39
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              unclear
              Passage 5 · unclassified context
              application numbers
              1. BLA125085
              brand names
              1. Avastin
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              1010
              end exclusive
              true
              exact text
              ment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
              start
              569
              current approval status
              not_reconciled
              duplicate text group
              dup-b1f7ce4d79cd556f5641
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. BEVACIZUMAB
              id
              ind-span-8fa507cd69b6e4659e2f
              label id
              8debebf6-af94-4ba7-8d67-c801f4ea27eb
              positive predicate support span
              Source null
              qualifier mentions
              1. context exact
                ( 1.2 ) Recurrent glioblastoma in adults.
                kind
                age
                polarity
                not_inferred
                span
                end
                809
                end exclusive
                true
                exact text
                adults
                label id
                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                start
                803
              2. context exact
                ( 1.2 ) Recurrent glioblastoma in adults.
                kind
                stage_or_setting
                polarity
                not_inferred
                span
                end
                809
                end exclusive
                true
                exact text
                Recurrent glioblastoma in adults
                label id
                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                start
                777
              regulatory links
                schema version
                0.1.0
                source batch sha256
                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                source defined aliases
                1. abbreviation
                  NSCLC
                  definition exact
                  non–small cell lung cancer
                  definition span
                  end
                  2647
                  end exclusive
                  true
                  exact text
                  non–small cell lung cancer (NSCLC)
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                  start
                  2613
                source span
                end
                810
                end exclusive
                true
                exact text
                ( 1.2 ) Recurrent glioblastoma in adults.
                label id
                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                start
                769
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                spl effective date
                2025-01-06
                spl set id
                939b5d1f-9fb2-4499-80ef-0607aa6b114e
                spl version
                39
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                unclear
                Passage 6 · unclassified context
                application numbers
                1. BLA125085
                brand names
                1. Avastin
                classification reasons
                1. no_unambiguous_positive_indication_predicate
                clinical review status
                pending
                content role
                unclassified_context
                context span
                end
                1087
                end exclusive
                true
                exact text
                , locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary periton
                label id
                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                start
                611
                current approval status
                not_reconciled
                duplicate text group
                dup-d7519cb554db28bc988d
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. BEVACIZUMAB
                id
                ind-span-e0b997507536e43a6303
                label id
                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                positive predicate support span
                Source null
                qualifier mentions
                1. context exact
                  ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa.
                  kind
                  biomarker
                  polarity
                  not_inferred
                  span
                  end
                  862
                  end exclusive
                  true
                  exact text
                  Metastatic renal cell carcinoma in combinat
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                  start
                  819
                2. context exact
                  ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa.
                  kind
                  stage_or_setting
                  polarity
                  not_inferred
                  span
                  end
                  864
                  end exclusive
                  true
                  exact text
                  Metastatic renal cell carcinoma in combinatio
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                  start
                  819
                3. context exact
                  ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa.
                  kind
                  regimen
                  polarity
                  not_inferred
                  span
                  end
                  886
                  end exclusive
                  true
                  exact text
                  in combination with interferon alfa
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                  start
                  851
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                  source defined aliases
                  1. abbreviation
                    NSCLC
                    definition exact
                    non–small cell lung cancer
                    definition span
                    end
                    2647
                    end exclusive
                    true
                    exact text
                    non–small cell lung cancer (NSCLC)
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    2613
                  source span
                  end
                  887
                  end exclusive
                  true
                  exact text
                  ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa.
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                  start
                  811
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                  spl effective date
                  2025-01-06
                  spl set id
                  939b5d1f-9fb2-4499-80ef-0607aa6b114e
                  spl version
                  39
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  unclear
                  Passage 7 · unclassified context
                  application numbers
                  1. BLA125085
                  brand names
                  1. Avastin
                  classification reasons
                  1. no_unambiguous_positive_indication_predicate
                  clinical review status
                  pending
                  content role
                  unclassified_context
                  context span
                  end
                  1224
                  end exclusive
                  true
                  exact text
                  cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                  start
                  688
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-8235c1abc0ca8ba40023
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. BEVACIZUMAB
                  id
                  ind-span-1cb618d4e9fd77f2d88f
                  label id
                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                  positive predicate support span
                  Source null
                  qualifier mentions
                  1. context exact
                    ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxe
                    kind
                    biomarker
                    polarity
                    not_inferred
                    span
                    end
                    948
                    end exclusive
                    true
                    exact text
                    metastatic cervical cancer
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    922
                  2. context exact
                    ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclita
                    kind
                    stage_or_setting
                    polarity
                    not_inferred
                    span
                    end
                    917
                    end exclusive
                    true
                    exact text
                    recurrent
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    908
                  3. context exact
                    ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxe
                    kind
                    stage_or_setting
                    polarity
                    not_inferred
                    span
                    end
                    948
                    end exclusive
                    true
                    exact text
                    metastatic cervical cancer
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    922
                  4. context exact
                    1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
                    kind
                    regimen
                    polarity
                    not_inferred
                    span
                    end
                    1023
                    end exclusive
                    true
                    exact text
                    in combination with paclitaxel and cisplatin, or paclitaxel and topotecan
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    950
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                    source defined aliases
                    1. abbreviation
                      NSCLC
                      definition exact
                      non–small cell lung cancer
                      definition span
                      end
                      2647
                      end exclusive
                      true
                      exact text
                      non–small cell lung cancer (NSCLC)
                      label id
                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                      start
                      2613
                    source span
                    end
                    1024
                    end exclusive
                    true
                    exact text
                    ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    888
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                    spl effective date
                    2025-01-06
                    spl set id
                    939b5d1f-9fb2-4499-80ef-0607aa6b114e
                    spl version
                    39
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    unclear
                    Passage 8 · unclassified context
                    application numbers
                    1. BLA125085
                    brand names
                    1. Avastin
                    classification reasons
                    1. no_unambiguous_positive_indication_predicate
                    clinical review status
                    pending
                    content role
                    unclassified_context
                    context span
                    end
                    1458
                    end exclusive
                    true
                    exact text
                    atic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination w
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                    start
                    825
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-9ecffbee56b9894a5451
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. BEVACIZUMAB
                    id
                    ind-span-7f6a06819643c6fc2b9d
                    label id
                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                    positive predicate support span
                    Source null
                    qualifier mentions
                    1. context exact
                      lial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 )
                      kind
                      regimen
                      polarity
                      not_inferred
                      span
                      end
                      1254
                      end exclusive
                      true
                      exact text
                      in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1
                      label id
                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                      start
                      1099
                    regulatory links
                      schema version
                      0.1.0
                      source batch sha256
                      424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                      source defined aliases
                      1. abbreviation
                        NSCLC
                        definition exact
                        non–small cell lung cancer
                        definition span
                        end
                        2647
                        end exclusive
                        true
                        exact text
                        non–small cell lung cancer (NSCLC)
                        label id
                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                        start
                        2613
                      source span
                      end
                      1258
                      end exclusive
                      true
                      exact text
                      ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 )
                      label id
                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                      start
                      1025
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                      spl effective date
                      2025-01-06
                      spl set id
                      939b5d1f-9fb2-4499-80ef-0607aa6b114e
                      spl version
                      39
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      unclear
                      Passage 9 · unclassified context
                      application numbers
                      1. BLA125085
                      brand names
                      1. Avastin
                      classification reasons
                      1. no_unambiguous_positive_indication_predicate
                      clinical review status
                      pending
                      content role
                      unclassified_context
                      context span
                      end
                      1641
                      end exclusive
                      true
                      exact text
                      ian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) i
                      label id
                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                      start
                      1059
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-782c97549489eb6e0483
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. BEVACIZUMAB
                      id
                      ind-span-54b0a364a04e44c4d176
                      label id
                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                      positive predicate support span
                      Source null
                      qualifier mentions
                      1. context exact
                        liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 )
                        kind
                        stage_or_setting
                        polarity
                        not_inferred
                        span
                        end
                        1404
                        end exclusive
                        true
                        exact text
                        recurrent disease who received no more than
                        label id
                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                        start
                        1360
                      2. context exact
                        in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 )
                        kind
                        regimen
                        polarity
                        not_inferred
                        span
                        end
                        1437
                        end exclusive
                        true
                        exact text
                        in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1
                        label id
                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                        start
                        1259
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                        source defined aliases
                        1. abbreviation
                          NSCLC
                          definition exact
                          non–small cell lung cancer
                          definition span
                          end
                          2647
                          end exclusive
                          true
                          exact text
                          non–small cell lung cancer (NSCLC)
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          2613
                        source span
                        end
                        1441
                        end exclusive
                        true
                        exact text
                        in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 )
                        label id
                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                        start
                        1259
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                        spl effective date
                        2025-01-06
                        spl set id
                        939b5d1f-9fb2-4499-80ef-0607aa6b114e
                        spl version
                        39
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        unclear
                        Passage 10 · unclassified context
                        application numbers
                        1. BLA125085
                        brand names
                        1. Avastin
                        classification reasons
                        1. no_unambiguous_positive_indication_predicate
                        clinical review status
                        pending
                        content role
                        unclassified_context
                        context span
                        end
                        1991
                        end exclusive
                        true
                        exact text
                        esection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 ) 1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal c
                        label id
                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                        start
                        1242
                        current approval status
                        not_reconciled
                        duplicate text group
                        dup-3c6f0fa1ed465f6c8ae2
                        extraction review status
                        automated_candidate_pending_source_review
                        generic names
                        1. BEVACIZUMAB
                        id
                        ind-span-10bb28fe6761f7d72e30
                        label id
                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                        positive predicate support span
                        Source null
                        qualifier mentions
                        1. context exact
                          olizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )
                          kind
                          biomarker
                          polarity
                          not_inferred
                          span
                          end
                          1767
                          end exclusive
                          true
                          exact text
                          metastatic HCC who have not received prior
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1724
                        2. context exact
                          llowed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atez
                          kind
                          stage_or_setting
                          polarity
                          not_inferred
                          span
                          end
                          1604
                          end exclusive
                          true
                          exact text
                          recurrent disease ( 1
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1583
                        3. context exact
                          nation with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )
                          kind
                          stage_or_setting
                          polarity
                          not_inferred
                          span
                          end
                          1755
                          end exclusive
                          true
                          exact text
                          unresectable or metastatic HCC who have not rec
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1708
                        4. context exact
                          s with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )
                          kind
                          prior_therapy_or_line
                          polarity
                          not_inferred
                          span
                          end
                          1787
                          end exclusive
                          true
                          exact text
                          prior systemic therapy ( 1
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1761
                        5. context exact
                          in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atez
                          kind
                          regimen
                          polarity
                          not_inferred
                          span
                          end
                          1604
                          end exclusive
                          true
                          exact text
                          in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1442
                        6. context exact
                          ve recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )
                          kind
                          regimen
                          polarity
                          not_inferred
                          span
                          end
                          1787
                          end exclusive
                          true
                          exact text
                          in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1640
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                          source defined aliases
                          1. abbreviation
                            NSCLC
                            definition exact
                            non–small cell lung cancer
                            definition span
                            end
                            2647
                            end exclusive
                            true
                            exact text
                            non–small cell lung cancer (NSCLC)
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            2613
                          source span
                          end
                          1791
                          end exclusive
                          true
                          exact text
                          in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1442
                          source url
                          https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                          spl effective date
                          2025-01-06
                          spl set id
                          939b5d1f-9fb2-4499-80ef-0607aa6b114e
                          spl version
                          39
                          structured fields status
                          not_extracted_no_values_inferred_from_mentions
                          structured indication
                          age
                          Source null
                          approval pathway
                          Source null
                          biomarker and test
                          Source null
                          disease stage
                          Source null
                          limitations
                          Source null
                          line
                          Source null
                          prior therapy
                          Source null
                          regimen
                          Source null
                          tumor histology
                          Source null
                          use intent
                          unclear
                          Passage 11 · positive indication candidate
                          application numbers
                          1. BLA125085
                          brand names
                          1. Avastin
                          classification reasons
                          1. explicit_positive_indication_predicate
                          2. tumor_or_malignant_hematology_words_in_positive_statement
                          clinical review status
                          pending
                          content role
                          positive_indication_candidate
                          context span
                          end
                          2204
                          end exclusive
                          true
                          exact text
                          disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 ) 1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC). Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1592
                          current approval status
                          not_reconciled
                          duplicate text group
                          dup-a4e8549fa13c66710cc4
                          extraction review status
                          automated_candidate_pending_source_review
                          generic names
                          1. BEVACIZUMAB
                          id
                          ind-span-18e38758c1f4966cbed4
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          positive predicate support span
                          end
                          1911
                          end exclusive
                          true
                          exact text
                          is indicated
                          label id
                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                          start
                          1899
                          qualifier mentions
                          1. context exact
                            1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemoth
                            kind
                            biomarker
                            polarity
                            not_inferred
                            span
                            end
                            1832
                            end exclusive
                            true
                            exact text
                            Metastatic Colorectal Cancer Avastin
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1796
                          2. context exact
                            ted for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC).
                            kind
                            biomarker
                            polarity
                            not_inferred
                            span
                            end
                            2003
                            end exclusive
                            true
                            exact text
                            metastatic colorectal cancer (mCRC)
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1968
                          3. context exact
                            1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemoth
                            kind
                            stage_or_setting
                            polarity
                            not_inferred
                            span
                            end
                            1832
                            end exclusive
                            true
                            exact text
                            Metastatic Colorectal Cancer Avastin
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1796
                          4. context exact
                            ted for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC).
                            kind
                            stage_or_setting
                            polarity
                            not_inferred
                            span
                            end
                            2003
                            end exclusive
                            true
                            exact text
                            metastatic colorectal cancer (mCRC)
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1968
                          5. context exact
                            orouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC).
                            kind
                            prior_therapy_or_line
                            polarity
                            not_inferred
                            span
                            end
                            2003
                            end exclusive
                            true
                            exact text
                            second-line treatment of patients with metastatic colorectal cancer (mCRC)
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1929
                          6. context exact
                            1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC).
                            kind
                            regimen
                            polarity
                            not_inferred
                            span
                            end
                            2003
                            end exclusive
                            true
                            exact text
                            in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC)
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1834
                          regulatory links
                            schema version
                            0.1.0
                            source batch sha256
                            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                            source defined aliases
                            1. abbreviation
                              NSCLC
                              definition exact
                              non–small cell lung cancer
                              definition span
                              end
                              2647
                              end exclusive
                              true
                              exact text
                              non–small cell lung cancer (NSCLC)
                              label id
                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                              start
                              2613
                            source span
                            end
                            2004
                            end exclusive
                            true
                            exact text
                            1.1 Metastatic Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC).
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1792
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                            spl effective date
                            2025-01-06
                            spl set id
                            939b5d1f-9fb2-4499-80ef-0607aa6b114e
                            spl version
                            39
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            tumor_directed_candidate
                            Passage 12 · positive indication candidate
                            application numbers
                            1. BLA125085
                            brand names
                            1. Avastin
                            classification reasons
                            1. explicit_positive_indication_predicate
                            2. no_tumor_directed_keyword_in_positive_statement
                            clinical review status
                            pending
                            content role
                            positive_indication_candidate
                            context span
                            end
                            2455
                            end exclusive
                            true
                            exact text
                            c Colorectal Cancer Avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC). Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ]. 1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination wit
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            1805
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-5299444056933465469f
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. BEVACIZUMAB
                            id
                            ind-span-d8ff84fffba43d26cfc9
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            positive predicate support span
                            end
                            2127
                            end exclusive
                            true
                            exact text
                            is indicated
                            label id
                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                            start
                            2115
                            qualifier mentions
                            1. context exact
                              midine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen.
                              kind
                              prior_therapy_or_line
                              polarity
                              not_inferred
                              span
                              end
                              2254
                              end exclusive
                              true
                              exact text
                              second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen
                              label id
                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                              start
                              2136
                            2. context exact
                              Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regime
                              kind
                              regimen
                              polarity
                              not_inferred
                              span
                              end
                              2193
                              end exclusive
                              true
                              exact text
                              in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have prog
                              label id
                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                              start
                              2014
                            regulatory links
                              schema version
                              0.1.0
                              source batch sha256
                              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                              source defined aliases
                              1. abbreviation
                                NSCLC
                                definition exact
                                non–small cell lung cancer
                                definition span
                                end
                                2647
                                end exclusive
                                true
                                exact text
                                non–small cell lung cancer (NSCLC)
                                label id
                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                start
                                2613
                              source span
                              end
                              2255
                              end exclusive
                              true
                              exact text
                              Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen.
                              label id
                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                              start
                              2005
                              source url
                              https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                              spl effective date
                              2025-01-06
                              spl set id
                              939b5d1f-9fb2-4499-80ef-0607aa6b114e
                              spl version
                              39
                              structured fields status
                              not_extracted_no_values_inferred_from_mentions
                              structured indication
                              age
                              Source null
                              approval pathway
                              Source null
                              biomarker and test
                              Source null
                              disease stage
                              Source null
                              limitations
                              Source null
                              line
                              Source null
                              prior therapy
                              Source null
                              regimen
                              Source null
                              tumor histology
                              Source null
                              use intent
                              non_oncology_or_unclear_candidate
                              Passage 13 · limitation of use
                              application numbers
                              1. BLA125085
                              brand names
                              1. Avastin
                              classification reasons
                              1. negative_or_not_established_clause
                              clinical review status
                              pending
                              content role
                              limitation_of_use
                              context span
                              end
                              2572
                              end exclusive
                              true
                              exact text
                              tecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ]. 1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanc
                              label id
                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                              start
                              2056
                              current approval status
                              not_reconciled
                              duplicate text group
                              dup-95666ff18f06045b5c25
                              extraction review status
                              automated_candidate_pending_source_review
                              generic names
                              1. BEVACIZUMAB
                              id
                              ind-span-3c1a2a0c60cd99a22d83
                              label id
                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                              positive predicate support span
                              Source null
                              qualifier mentions
                              1. context exact
                                Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ].
                                kind
                                stage_or_setting
                                polarity
                                not_inferred
                                span
                                end
                                2349
                                end exclusive
                                true
                                exact text
                                adjuvant treatment of colon cancer [see Cli
                                label id
                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                start
                                2306
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                source defined aliases
                                1. abbreviation
                                  NSCLC
                                  definition exact
                                  non–small cell lung cancer
                                  definition span
                                  end
                                  2647
                                  end exclusive
                                  true
                                  exact text
                                  non–small cell lung cancer (NSCLC)
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2613
                                source span
                                end
                                2372
                                end exclusive
                                true
                                exact text
                                Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ].
                                label id
                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                start
                                2256
                                source url
                                https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                spl effective date
                                2025-01-06
                                spl set id
                                939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                spl version
                                39
                                structured fields status
                                not_extracted_no_values_inferred_from_mentions
                                structured indication
                                age
                                Source null
                                approval pathway
                                Source null
                                biomarker and test
                                Source null
                                disease stage
                                Source null
                                limitations
                                Source null
                                line
                                Source null
                                prior therapy
                                Source null
                                regimen
                                Source null
                                tumor histology
                                Source null
                                use intent
                                not_applicable
                                Passage 14 · positive indication candidate
                                application numbers
                                1. BLA125085
                                brand names
                                1. Avastin
                                classification reasons
                                1. explicit_positive_indication_predicate
                                2. tumor_or_malignant_hematology_words_in_positive_statement
                                clinical review status
                                pending
                                content role
                                positive_indication_candidate
                                context span
                                end
                                2848
                                end exclusive
                                true
                                exact text
                                h mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical Studies (14.2) ]. 1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC). 1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults. 1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indic
                                label id
                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                start
                                2173
                                current approval status
                                not_reconciled
                                duplicate text group
                                dup-886711eeaf90d46c53df
                                extraction review status
                                automated_candidate_pending_source_review
                                generic names
                                1. BEVACIZUMAB
                                id
                                ind-span-18e99c68a093fa001ff7
                                label id
                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                positive predicate support span
                                end
                                2497
                                end exclusive
                                true
                                exact text
                                is indicated
                                label id
                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                start
                                2485
                                qualifier mentions
                                1. context exact
                                  patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC).
                                  kind
                                  biomarker
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  2632
                                  end exclusive
                                  true
                                  exact text
                                  metastatic non–squamous non–small cell lung
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2589
                                2. context exact
                                  is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non
                                  kind
                                  stage_or_setting
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  2556
                                  end exclusive
                                  true
                                  exact text
                                  unresectable
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2544
                                3. context exact
                                  for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung c
                                  kind
                                  stage_or_setting
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  2574
                                  end exclusive
                                  true
                                  exact text
                                  locally advanced
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2558
                                4. context exact
                                  treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC).
                                  kind
                                  stage_or_setting
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  2620
                                  end exclusive
                                  true
                                  exact text
                                  recurrent or metastatic non–squamous non–sma
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2576
                                5. context exact
                                  1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squ
                                  kind
                                  prior_therapy_or_line
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  2547
                                  end exclusive
                                  true
                                  exact text
                                  First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unr
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2377
                                6. context exact
                                  First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC).
                                  kind
                                  regimen
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  2616
                                  end exclusive
                                  true
                                  exact text
                                  in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2437
                                regulatory links
                                  schema version
                                  0.1.0
                                  source batch sha256
                                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                  source defined aliases
                                  1. abbreviation
                                    NSCLC
                                    definition exact
                                    non–small cell lung cancer
                                    definition span
                                    end
                                    2647
                                    end exclusive
                                    true
                                    exact text
                                    non–small cell lung cancer (NSCLC)
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2613
                                  source span
                                  end
                                  2648
                                  end exclusive
                                  true
                                  exact text
                                  1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC).
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2373
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                  spl effective date
                                  2025-01-06
                                  spl set id
                                  939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                  spl version
                                  39
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  tumor_directed_candidate
                                  Passage 15 · positive indication candidate
                                  application numbers
                                  1. BLA125085
                                  brand names
                                  1. Avastin
                                  classification reasons
                                  1. explicit_positive_indication_predicate
                                  2. tumor_or_malignant_hematology_words_in_positive_statement
                                  clinical review status
                                  pending
                                  content role
                                  positive_indication_candidate
                                  context span
                                  end
                                  2957
                                  end exclusive
                                  true
                                  exact text
                                  on with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC). 1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults. 1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). 1.5 Persistent, Recurrent, or Metastatic Ce
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2449
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-c84f5d99f4fa22702a28
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. BEVACIZUMAB
                                  id
                                  ind-span-73ea58e85734ad6bb3b4
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  positive predicate support span
                                  end
                                  2696
                                  end exclusive
                                  true
                                  exact text
                                  is indicated
                                  label id
                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                  start
                                  2684
                                  qualifier mentions
                                  1. context exact
                                    icated for the treatment of recurrent glioblastoma (GBM) in adults.
                                    kind
                                    age
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    2756
                                    end exclusive
                                    true
                                    exact text
                                    adults
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2750
                                  2. context exact
                                    1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
                                    kind
                                    stage_or_setting
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    2697
                                    end exclusive
                                    true
                                    exact text
                                    Recurrent Glioblastoma Avastin is indicated
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2653
                                  3. context exact
                                    rent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
                                    kind
                                    stage_or_setting
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    2756
                                    end exclusive
                                    true
                                    exact text
                                    recurrent glioblastoma (GBM) in adults
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2718
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                    source defined aliases
                                    1. abbreviation
                                      NSCLC
                                      definition exact
                                      non–small cell lung cancer
                                      definition span
                                      end
                                      2647
                                      end exclusive
                                      true
                                      exact text
                                      non–small cell lung cancer (NSCLC)
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2613
                                    source span
                                    end
                                    2757
                                    end exclusive
                                    true
                                    exact text
                                    1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2649
                                    source url
                                    https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                    spl effective date
                                    2025-01-06
                                    spl set id
                                    939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                    spl version
                                    39
                                    structured fields status
                                    not_extracted_no_values_inferred_from_mentions
                                    structured indication
                                    age
                                    Source null
                                    approval pathway
                                    Source null
                                    biomarker and test
                                    Source null
                                    disease stage
                                    Source null
                                    limitations
                                    Source null
                                    line
                                    Source null
                                    prior therapy
                                    Source null
                                    regimen
                                    Source null
                                    tumor histology
                                    Source null
                                    use intent
                                    tumor_directed_candidate
                                    Passage 16 · positive indication candidate
                                    application numbers
                                    1. BLA125085
                                    brand names
                                    1. Avastin
                                    classification reasons
                                    1. explicit_positive_indication_predicate
                                    2. tumor_or_malignant_hematology_words_in_positive_statement
                                    clinical review status
                                    pending
                                    content role
                                    positive_indication_candidate
                                    context span
                                    end
                                    3113
                                    end exclusive
                                    true
                                    exact text
                                    locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC). 1.3 Recurrent Glioblastoma Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults. 1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). 1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent,
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2558
                                    current approval status
                                    not_reconciled
                                    duplicate text group
                                    dup-d0cba08d8b73c70dd2d8
                                    extraction review status
                                    automated_candidate_pending_source_review
                                    generic names
                                    1. BEVACIZUMAB
                                    id
                                    ind-span-9ef9865c1c63c4f242c9
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    positive predicate support span
                                    end
                                    2852
                                    end exclusive
                                    true
                                    exact text
                                    is indicated
                                    label id
                                    8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                    start
                                    2840
                                    qualifier mentions
                                    1. context exact
                                      1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the
                                      kind
                                      biomarker
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      2801
                                      end exclusive
                                      true
                                      exact text
                                      Metastatic Renal Cell Carcinoma Avastin
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2762
                                    2. context exact
                                      ion with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
                                      kind
                                      biomarker
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      2912
                                      end exclusive
                                      true
                                      exact text
                                      metastatic renal cell carcinoma (mRCC)
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2874
                                    3. context exact
                                      1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the
                                      kind
                                      stage_or_setting
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      2801
                                      end exclusive
                                      true
                                      exact text
                                      Metastatic Renal Cell Carcinoma Avastin
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2762
                                    4. context exact
                                      ion with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
                                      kind
                                      stage_or_setting
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      2912
                                      end exclusive
                                      true
                                      exact text
                                      metastatic renal cell carcinoma (mRCC)
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2874
                                    5. context exact
                                      1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
                                      kind
                                      regimen
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      2912
                                      end exclusive
                                      true
                                      exact text
                                      in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC)
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2803
                                    regulatory links
                                      schema version
                                      0.1.0
                                      source batch sha256
                                      424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                      source defined aliases
                                      1. abbreviation
                                        NSCLC
                                        definition exact
                                        non–small cell lung cancer
                                        definition span
                                        end
                                        2647
                                        end exclusive
                                        true
                                        exact text
                                        non–small cell lung cancer (NSCLC)
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2613
                                      source span
                                      end
                                      2913
                                      end exclusive
                                      true
                                      exact text
                                      1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2758
                                      source url
                                      https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                      spl effective date
                                      2025-01-06
                                      spl set id
                                      939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                      spl version
                                      39
                                      structured fields status
                                      not_extracted_no_values_inferred_from_mentions
                                      structured indication
                                      age
                                      Source null
                                      approval pathway
                                      Source null
                                      biomarker and test
                                      Source null
                                      disease stage
                                      Source null
                                      limitations
                                      Source null
                                      line
                                      Source null
                                      prior therapy
                                      Source null
                                      regimen
                                      Source null
                                      tumor histology
                                      Source null
                                      use intent
                                      tumor_directed_candidate
                                      Passage 17 · positive indication candidate
                                      application numbers
                                      1. BLA125085
                                      brand names
                                      1. Avastin
                                      classification reasons
                                      1. explicit_positive_indication_predicate
                                      2. tumor_or_malignant_hematology_words_in_positive_statement
                                      clinical review status
                                      pending
                                      content role
                                      positive_indication_candidate
                                      context span
                                      end
                                      3355
                                      end exclusive
                                      true
                                      exact text
                                      of recurrent glioblastoma (GBM) in adults. 1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). 1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. 1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      2714
                                      current approval status
                                      not_reconciled
                                      duplicate text group
                                      dup-3001d4a4dac213bfea1f
                                      extraction review status
                                      automated_candidate_pending_source_review
                                      generic names
                                      1. BEVACIZUMAB
                                      id
                                      ind-span-fcccbdf22a16b1011e03
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      positive predicate support span
                                      end
                                      3066
                                      end exclusive
                                      true
                                      exact text
                                      is indicated
                                      label id
                                      8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                      start
                                      3054
                                      qualifier mentions
                                      1. context exact
                                        1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel
                                        kind
                                        biomarker
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        2978
                                        end exclusive
                                        true
                                        exact text
                                        Metastatic Cervical Cancer Avastin
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2944
                                      2. context exact
                                        or the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
                                        kind
                                        biomarker
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        3154
                                        end exclusive
                                        true
                                        exact text
                                        metastatic cervical cancer
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        3128
                                      3. context exact
                                        1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with
                                        kind
                                        stage_or_setting
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        2939
                                        end exclusive
                                        true
                                        exact text
                                        Recurrent
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2930
                                      4. context exact
                                        1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel
                                        kind
                                        stage_or_setting
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        2978
                                        end exclusive
                                        true
                                        exact text
                                        Metastatic Cervical Cancer Avastin
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2944
                                      5. context exact
                                        is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
                                        kind
                                        stage_or_setting
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        3123
                                        end exclusive
                                        true
                                        exact text
                                        recurrent
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        3114
                                      6. context exact
                                        or the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
                                        kind
                                        stage_or_setting
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        3154
                                        end exclusive
                                        true
                                        exact text
                                        metastatic cervical cancer
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        3128
                                      7. context exact
                                        rsistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
                                        kind
                                        regimen
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        3154
                                        end exclusive
                                        true
                                        exact text
                                        in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2980
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                        source defined aliases
                                        1. abbreviation
                                          NSCLC
                                          definition exact
                                          non–small cell lung cancer
                                          definition span
                                          end
                                          2647
                                          end exclusive
                                          true
                                          exact text
                                          non–small cell lung cancer (NSCLC)
                                          label id
                                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                          start
                                          2613
                                        source span
                                        end
                                        3155
                                        end exclusive
                                        true
                                        exact text
                                        1.5 Persistent, Recurrent, or Metastatic Cervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2914
                                        source url
                                        https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                        spl effective date
                                        2025-01-06
                                        spl set id
                                        939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                        spl version
                                        39
                                        structured fields status
                                        not_extracted_no_values_inferred_from_mentions
                                        structured indication
                                        age
                                        Source null
                                        approval pathway
                                        Source null
                                        biomarker and test
                                        Source null
                                        disease stage
                                        Source null
                                        limitations
                                        Source null
                                        line
                                        Source null
                                        prior therapy
                                        Source null
                                        regimen
                                        Source null
                                        tumor histology
                                        Source null
                                        use intent
                                        tumor_directed_candidate
                                        Passage 18 · positive indication candidate
                                        application numbers
                                        1. BLA125085
                                        brand names
                                        1. Avastin
                                        classification reasons
                                        1. explicit_positive_indication_predicate
                                        2. tumor_or_malignant_hematology_words_in_positive_statement
                                        clinical review status
                                        pending
                                        content role
                                        positive_indication_candidate
                                        context span
                                        end
                                        3687
                                        end exclusive
                                        true
                                        exact text
                                        ervical Cancer Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. 1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        2956
                                        current approval status
                                        not_reconciled
                                        duplicate text group
                                        dup-51668be15bb6ae3cde98
                                        extraction review status
                                        automated_candidate_pending_source_review
                                        generic names
                                        1. BEVACIZUMAB
                                        id
                                        ind-span-e4305bda1b37c1bed591
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        positive predicate support span
                                        end
                                        3333
                                        end exclusive
                                        true
                                        exact text
                                        is indicated
                                        label id
                                        8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                        start
                                        3321
                                        qualifier mentions
                                        1. context exact
                                          rian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgi
                                          kind
                                          regimen
                                          polarity
                                          not_inferred
                                          span
                                          end
                                          3413
                                          end exclusive
                                          true
                                          exact text
                                          in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopia
                                          label id
                                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                          start
                                          3234
                                        regulatory links
                                          schema version
                                          0.1.0
                                          source batch sha256
                                          424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                          source defined aliases
                                          1. abbreviation
                                            NSCLC
                                            definition exact
                                            non–small cell lung cancer
                                            definition span
                                            end
                                            2647
                                            end exclusive
                                            true
                                            exact text
                                            non–small cell lung cancer (NSCLC)
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                            start
                                            2613
                                          source span
                                          end
                                          3487
                                          end exclusive
                                          true
                                          exact text
                                          1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
                                          label id
                                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                          start
                                          3156
                                          source url
                                          https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                          spl effective date
                                          2025-01-06
                                          spl set id
                                          939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                          spl version
                                          39
                                          structured fields status
                                          not_extracted_no_values_inferred_from_mentions
                                          structured indication
                                          age
                                          Source null
                                          approval pathway
                                          Source null
                                          biomarker and test
                                          Source null
                                          disease stage
                                          Source null
                                          limitations
                                          Source null
                                          line
                                          Source null
                                          prior therapy
                                          Source null
                                          regimen
                                          Source null
                                          tumor histology
                                          Source null
                                          use intent
                                          tumor_directed_candidate
                                          Passage 19 · positive indication candidate
                                          application numbers
                                          1. BLA125085
                                          brand names
                                          1. Avastin
                                          classification reasons
                                          1. explicit_positive_indication_predicate
                                          2. tumor_or_malignant_hematology_words_in_positive_statement
                                          clinical review status
                                          pending
                                          content role
                                          positive_indication_candidate
                                          context span
                                          end
                                          3973
                                          end exclusive
                                          true
                                          exact text
                                          ed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive
                                          label id
                                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                          start
                                          3288
                                          current approval status
                                          not_reconciled
                                          duplicate text group
                                          dup-debd8672f01a5d476cae
                                          extraction review status
                                          automated_candidate_pending_source_review
                                          generic names
                                          1. BEVACIZUMAB
                                          id
                                          ind-span-b8963e79342994e1b581
                                          label id
                                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                          positive predicate support span
                                          end
                                          3588
                                          end exclusive
                                          true
                                          exact text
                                          is indicated
                                          label id
                                          8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                          start
                                          3576
                                          qualifier mentions
                                          1. context exact
                                            cated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received n
                                            kind
                                            stage_or_setting
                                            polarity
                                            not_inferred
                                            span
                                            end
                                            3671
                                            end exclusive
                                            true
                                            exact text
                                            recurrent epithelial ovarian
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                            start
                                            3643
                                          2. context exact
                                            Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no mor
                                            kind
                                            regimen
                                            polarity
                                            not_inferred
                                            span
                                            end
                                            3676
                                            end exclusive
                                            true
                                            exact text
                                            in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fal
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                            start
                                            3497
                                          regulatory links
                                            schema version
                                            0.1.0
                                            source batch sha256
                                            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                            source defined aliases
                                            1. abbreviation
                                              NSCLC
                                              definition exact
                                              non–small cell lung cancer
                                              definition span
                                              end
                                              2647
                                              end exclusive
                                              true
                                              exact text
                                              non–small cell lung cancer (NSCLC)
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                              start
                                              2613
                                            source span
                                            end
                                            3773
                                            end exclusive
                                            true
                                            exact text
                                            Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                            start
                                            3488
                                            source url
                                            https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                            spl effective date
                                            2025-01-06
                                            spl set id
                                            939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                            spl version
                                            39
                                            structured fields status
                                            not_extracted_no_values_inferred_from_mentions
                                            structured indication
                                            age
                                            Source null
                                            approval pathway
                                            Source null
                                            biomarker and test
                                            Source null
                                            disease stage
                                            Source null
                                            limitations
                                            Source null
                                            line
                                            Source null
                                            prior therapy
                                            Source null
                                            regimen
                                            Source null
                                            tumor histology
                                            Source null
                                            use intent
                                            tumor_directed_candidate
                                            Passage 20 · positive indication candidate
                                            application numbers
                                            1. BLA125085
                                            brand names
                                            1. Avastin
                                            classification reasons
                                            1. explicit_positive_indication_predicate
                                            2. tumor_or_malignant_hematology_words_in_positive_statement
                                            clinical review status
                                            pending
                                            content role
                                            positive_indication_candidate
                                            context span
                                            end
                                            4249
                                            end exclusive
                                            true
                                            exact text
                                            , is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 1.7 Hepatocellular Carcinoma Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                            start
                                            3574
                                            current approval status
                                            not_reconciled
                                            duplicate text group
                                            dup-f4492965685a84edce40
                                            extraction review status
                                            automated_candidate_pending_source_review
                                            generic names
                                            1. BEVACIZUMAB
                                            id
                                            ind-span-b6326a514c0a80c3d750
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            positive predicate support span
                                            end
                                            3919
                                            end exclusive
                                            true
                                            exact text
                                            is indicated
                                            label id
                                            8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                            start
                                            3907
                                            qualifier mentions
                                            1. context exact
                                              cated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
                                              kind
                                              stage_or_setting
                                              polarity
                                              not_inferred
                                              span
                                              end
                                              4002
                                              end exclusive
                                              true
                                              exact text
                                              recurrent epithelial ovarian
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                              start
                                              3974
                                            2. context exact
                                              Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or
                                              kind
                                              regimen
                                              polarity
                                              not_inferred
                                              span
                                              end
                                              3962
                                              end exclusive
                                              true
                                              exact text
                                              in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinu
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                              start
                                              3783
                                            regulatory links
                                              schema version
                                              0.1.0
                                              source batch sha256
                                              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                              source defined aliases
                                              1. abbreviation
                                                NSCLC
                                                definition exact
                                                non–small cell lung cancer
                                                definition span
                                                end
                                                2647
                                                end exclusive
                                                true
                                                exact text
                                                non–small cell lung cancer (NSCLC)
                                                label id
                                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                start
                                                2613
                                              source span
                                              end
                                              4049
                                              end exclusive
                                              true
                                              exact text
                                              Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                              start
                                              3774
                                              source url
                                              https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                              spl effective date
                                              2025-01-06
                                              spl set id
                                              939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                              spl version
                                              39
                                              structured fields status
                                              not_extracted_no_values_inferred_from_mentions
                                              structured indication
                                              age
                                              Source null
                                              approval pathway
                                              Source null
                                              biomarker and test
                                              Source null
                                              disease stage
                                              Source null
                                              limitations
                                              Source null
                                              line
                                              Source null
                                              prior therapy
                                              Source null
                                              regimen
                                              Source null
                                              tumor histology
                                              Source null
                                              use intent
                                              tumor_directed_candidate
                                              Passage 21 · positive indication candidate
                                              application numbers
                                              1. BLA125085
                                              brand names
                                              1. Avastin
                                              classification reasons
                                              1. explicit_positive_indication_predicate
                                              2. tumor_or_malignant_hematology_words_in_positive_statement
                                              clinical review status
                                              pending
                                              content role
                                              positive_indication_candidate
                                              context span
                                              end
                                              4273
                                              end exclusive
                                              true
                                              exact text
                                              and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 1.7 Hepatocellular Carcinoma Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                              start
                                              3850
                                              current approval status
                                              not_reconciled
                                              duplicate text group
                                              dup-ff4beb11d2d19c56eee4
                                              extraction review status
                                              automated_candidate_pending_source_review
                                              generic names
                                              1. BEVACIZUMAB
                                              id
                                              ind-span-693010a939a09e2fee99
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              positive predicate support span
                                              end
                                              4134
                                              end exclusive
                                              true
                                              exact text
                                              is indicated
                                              label id
                                              8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                              start
                                              4122
                                              qualifier mentions
                                              1. context exact
                                                ndicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
                                                kind
                                                biomarker
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                4229
                                                end exclusive
                                                true
                                                exact text
                                                metastatic hepatocellular carcinoma (HCC) w
                                                label id
                                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                start
                                                4186
                                              2. context exact
                                                ezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
                                                kind
                                                stage_or_setting
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                4217
                                                end exclusive
                                                true
                                                exact text
                                                unresectable or metastatic hepatocellular carci
                                                label id
                                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                start
                                                4170
                                              3. context exact
                                                static hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
                                                kind
                                                prior_therapy_or_line
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                4272
                                                end exclusive
                                                true
                                                exact text
                                                prior systemic therapy
                                                label id
                                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                start
                                                4250
                                              4. context exact
                                                1.7 Hepatocellular Carcinoma Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
                                                kind
                                                regimen
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                4267
                                                end exclusive
                                                true
                                                exact text
                                                in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic th
                                                label id
                                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                start
                                                4088
                                              regulatory links
                                                schema version
                                                0.1.0
                                                source batch sha256
                                                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                source defined aliases
                                                1. abbreviation
                                                  NSCLC
                                                  definition exact
                                                  non–small cell lung cancer
                                                  definition span
                                                  end
                                                  2647
                                                  end exclusive
                                                  true
                                                  exact text
                                                  non–small cell lung cancer (NSCLC)
                                                  label id
                                                  8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                  start
                                                  2613
                                                source span
                                                end
                                                4273
                                                end exclusive
                                                true
                                                exact text
                                                1.7 Hepatocellular Carcinoma Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
                                                label id
                                                8debebf6-af94-4ba7-8d67-c801f4ea27eb
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2b8c3ecb15e16c232339578003223e8e6e6c1982798a5c3c87d6721550ba2f8
                                                start
                                                4050
                                                source url
                                                https://api.fda.gov/drug/label.json?search=id%3A%228debebf6-af94-4ba7-8d67-c801f4ea27eb%22
                                                spl effective date
                                                2025-01-06
                                                spl set id
                                                939b5d1f-9fb2-4499-80ef-0607aa6b114e
                                                spl version
                                                39
                                                structured fields status
                                                not_extracted_no_values_inferred_from_mentions
                                                structured indication
                                                age
                                                Source null
                                                approval pathway
                                                Source null
                                                biomarker and test
                                                Source null
                                                disease stage
                                                Source null
                                                limitations
                                                Source null
                                                line
                                                Source null
                                                prior therapy
                                                Source null
                                                regimen
                                                Source null
                                                tumor histology
                                                Source null
                                                use intent
                                                tumor_directed_candidate

                                                Preserved source evidence · Not medical advice